source
- Arrowhead’s RNA drug cuts Alzheimer’s tau protein in early human studyArrowhead Pharmaceuticals reported early-stage data showing its subcutaneous RNA therapeutic can reach the brain and lower tau protein, a hallmark of Alzheimer’s disease. In a first-in-human trial…
- Zealand Pharma signs up to $1.3 billion AI partnership with Generate Biomedicines for protein-based obesity drugsZealand Pharma announced a partnership with Generate Biomedicines to develop new protein-based treatments targeting obesity and related metabolic conditions. The collaboration will use Generate's…